Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03541902 · ClinicalTrials.gov registry record · Phase 2

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

A Phase 2 study of Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
32
Enrollment target
3
Study locations

NCT03541902: Active Phase 2 study of Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.

NCT03541902 is a Phase 2 study of Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 32 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03541902, a Phase 2 study of Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
32 participants
Enrollment target
3
Study locations

Study Summary

The goal of this clinical research study is to compare the safety and effectiveness of cabozantinib and sunitinib when given to patients with metastatic (has spread) variant histology renal cell carcinoma (vhRCC), a type of kidney cancer. This is an investigational study. Cabozantinib and sunitinib are both FDA approved and commercially available for the treatment of advanced kidney cancer, including vhRCC. The study doctor can explain how the study drugs are designed to work. Up to 84 participants will be enrolled in this study. All will take part at MD Anderson.

Primary Outcome

PFS defined as the time from randomization to progression or death, regardless of cause, whichever comes first.

Conditions Studied

Renal Cell Carcinoma Metastatic Renal Cell Carcinoma Stage IV Renal Cell Cancer AJCC v8 Chromophobe Renal Cell Carcinoma Papillary Renal Cell Carcinoma Unclassified Renal Cell Carcinoma Sarcomatoid Renal Cell Carcinoma Malignant Neoplasms of Urinary Tract Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions

Interventions

  • DRUG Cabozantinib
  • DRUG Sunitinib Malate

Study Locations (3)

Texas

  • M D Anderson Cancer Center - Houston
  • MD Anderson Regional Care Center-Katy - Houston
  • MD Anderson Regional Care Center-Sugar Land - Sugar Land

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2018-05-15
Est. Completion 2027-07-31
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What the registry record for NCT03541902 still lists

NCT03541902 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (87% lower).

The record links to 9 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Cabozantinib is the first listed.

NCT03541902 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT03541902 about?

NCT03541902 is a clinical study titled "Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma". The goal of this clinical research study is to compare the safety and effectiveness of cabozantinib and sunitinib when given to patients with metastatic (has spread) variant histology renal cell carcinoma (vhRCC), a type of kidney cancer. This is an investigational study. Cabozantinib and sunitinib...

What is the current status of trial NCT03541902?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2018-05-15. Estimated completion is 2027-07-31.

What conditions does trial NCT03541902 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Chromophobe Renal Cell Carcinoma, Papillary Renal Cell Carcinoma.

What interventions are being tested in trial NCT03541902?

The interventions under investigation include: Cabozantinib (DRUG), Sunitinib Malate (DRUG).

Who is sponsoring clinical trial NCT03541902?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03541902 being conducted?

This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03541902's enrollment target sits among peer trials

32 90th of 121 higher than 30 of 121 other Renal Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03541902, the US trial registry maintained by the National Library of Medicine. NCT03541902 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.